title: The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.
abstract: Quantification of human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies is considered to be an important parameter in evaluating candidate vaccines. Most previous studies have failed to detect vaccine-induced antibodies against primary isolates, which are more resistant to antibody mediated neutralization compared with laboratory isolates, in neutralization assays. In this study, sera from a prime boost vaccination strategy of a phase I clinical trial were tested against six clade B primary HIV-1 isolates and single isolates of clades C and F. These sera produced statistically significant neutralization against primary isolates MN, SF13, SF162 and Han 2 but not the most resistant subtype B isolates (92US077 and 93US143) nor the subtype C and F isolates. These data suggest that the sera from vaccinated volunteers have subtype-specific neutralizing antibodies against primary HIV-1 isolates. We recommend using assays with extended incubation phases to monitor current HIV vaccine efficacy trials.
authors: Department of Microbiology, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
authors: Helen
authors: H
authors: Donners
authors: Tine
authors: T
authors: Vermoesen
authors: Betty
authors: B
authors: Willems
authors: David
authors: D
authors: Davis
authors: Guido
authors: G
authors: van der Groen
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000918:Antibody Specificity; D015704:CD4 Antigens / Q000276:immunology; D002460:Cell Line; D024882:Drug Resistance, Viral; D005456:Fluorescent Dyes; D015483:HIV Antibodies / Q000032:analysis / Q000096:biosynthesis*; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests
chemical_list: D016915:AIDS Vaccines; D015704:CD4 Antigens; D005456:Fluorescent Dyes; D015483:HIV Antibodies